| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2021-01-18 | ViGeneron (DE) Daiichi-Sankyo (Japan) | engineered adeno-associated virus (vgAAV) | undisclosed | research | Ophthalmological diseases | Research agreement |
| 2021-01-05 | Biogen (USA - MA) ViGeneron (DE) | gene therapy products based on adeno-associated virus (AAV) vectors | inherited eye diseases | collaboration licensing | Ophthalmological diseases | Licensing agreement |
| 2020-12-15 | Vectivbio (Switzerland) | nomination | Nomination | |||
| 2020-12-01 | ViGeneron (DE) WuXi Advanced Therapies (USA - PA) | VG901 | retinitis pigmentosa | development manufacturing | Ophthalmological diseases | Production agreement |
| 2020-11-04 | Vectivbio (Switzerland) | business development officers | nomination | Inflammatory diseases - Gastrointestinal diseases - Transplantation | Nomination | |
| 2020-09-16 | Vectivbio (Switzerland) | senior vice president and head of global clinical development and medical affairs | nomination | Inflammatory diseases - Gastrointestinal diseases - Transplantation | Nomination | |
| 2020-05-26 | 20Med Therapeutics (NL) | opening of new premises | Opening of new premises | |||
| 2020-03-23 | Soligenix (USA - NY) the University of Hawaii (USA) | COVID-19, coronavirus infection | research | Infectious diseases | Research agreement | |
| 2020-02-26 | Gemini Therapeutics (USA) - Singapore Eye Research Institute (SG) | new targets associated with age-related macular degeneration | Age-related Macular Degeneration (AMD), polypoidal choroidal vasculopathy | R&D | Ophthalmological diseases - Cardiovascular diseases | Research agreement |
| 2020-02-12 | Sangamo Therapeutics (USA - CA) | member of the board | nomination | Nomination | ||
| 2020-02-06 | Vectivbio (Switzerland) | chief commercial officer | nomination | Inflammatory diseases - Gastrointestinal diseases - Transplantation | Nomination | |
| 2019-12-23 | Sangamo Therapeutics (USA - CA) Pfizer (USA - NY) | gene therapy programs for hemophilia A, including SB-525 | hemophilia A | licensing - development - commercialisation | Rare diseases - Genetic diseases - Hematological diseases | Licensing agreement |
| 2019-11-26 | Sangamo Therapeutics (USA - CA) | member of the board | nomination | Nomination | ||
| 2019-11-08 | Sangamo Therapeutics (USA - CA) | scientific advisory board | nomination | Nomination | ||
| 2019-10-28 | 20Med Therapeutics (NL) | nomination | Nomination | |||
| 2019-09-30 | Sangamo Therapeutics (USA - CA) | senior vice president, chief medical officer | nomination | Nomination | ||
| 2019-09-13 | Gemini Therapeutics (USA) | CEO | nomination | Rare diseases - Genetic diseases- Ophthalmological diseases | Nomination | |
| 2019-07-31 | Sangamo Therapeutics (USA - CA) | executive vice president and general counsel | nomination | Nomination | ||
| 2019-06-19 | Genzyme (USA - MA), a Sanofi company (France) Voyager Therapeutics (USA - MA) | gene therapy programs for Parkinson’s disease, Friedreich’s ataxia, Huntington’s disease and other CNS disorders | Parkinson’s disease, Friedreich’s ataxia and Huntington’s disease and other CNS disorders | development - commercialisation | CNS diseases - Neurodegenerative diseases | Development agreement |
| 2019-05-20 | Voyager Therapeutics (USA-MA) | head of R&D | nomination | Neurological diseases - Neurodegenerative diseases | Nomination |
